Remove 2019 Remove Drug Research Remove Immune Response Remove Trials
article thumbnail

Harnessing the microbiome: The new frontier in drug discovery and testing 

Drug Discovery World

Paul Denslow , CEO, Intus Bio, discusses how a new approach to tracking gut bacteria can revolutionse our understanding of the microbiome and bring about new discoveries for therapeutics. It’s a long-held doctrine that there’s no effective method to track the microbiome during drug research and development. 365, (2019) .

article thumbnail

AI in gene delivery vector discovery and design

Drug Target Review

Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively. Wang D, Tai PW, Gao G.

article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. It also helps to quickly address unplanned changes.